Pluripotent stem cell therapy
POSTDOCTORAL RESEARCHERS
- Begoña Aran Corbella
SCIENTIFIC SUPPORT
- Bernd Kuebler
- Silvia Emilia Selvitella Luna
MANAGEMENT SUPPORT
- Anuska Linares Baraza
Regenerative Medicine
Regenerative Medicine
Scientific production
3
PAPERS
Average IF: 2,20
2
LED PAPERS
Average IF: 2,25
1 PUBLICATION IN FIRST QUARTILE
2 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Parriego M, Coll L, Carrasco B, Garcia S, Boada M, Polyzos NP, Vidal F, Veiga A. Blastocysts from partial compaction morulae are not defined by their early mistakes. Reprod Biomed Online. 2024 Apr;48(4):103729. doi: 10.1016/j.rbmo.2023.103729
- Massafret O, Barragán M, Álvarez-González L, Aran B, Martín-Mur B, Esteve-Codina A, Ruiz-Herrera A, Ibáñez E, Santaló J. The pluripotency state of human embryonic stem cells derived from single blastomeres of eight-cell embryos. Cells Dev. 2024 Sep;179:203935. doi: 10.1016/j.cdev.2024.203935
- Selvitella S, Franco MP, Aran B, Veiga A, Kuebler B. Generation of the CTRL EiPS J9 mR6F-8 iPSC line derived from healthy human outgrowth blood endothelial cells (BOECs) using mRNA reprogramming methodology. Stem Cell Res. 2024 Dec;81:103606. doi: 10.1016/j.scr.2024.103606
Research highlights
PROJECTS
1 Granted competitive project
3 Ongoing competitive projects
NETWORKS
SGR GRC-2021
Selected projects
- CA21151. HAPLO-iPS: GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS FROM HAPLO-SELECTED CORD BLOOD SAMPLES. COST ASSOCIATION. Budget: 504.499,99€. 2022-2026. PI: VEIGA LLUCH, ANA.
- PT23/00092. Generación de líneas de células madre pluripotentes para investigación y aplicación clínica. Instituto de Salud Carlos III. Budget: 226.954€. 2024-2026. PI: VEIGA LLUCH, ANA.
- PI21/01122. Edición genómica mediante CRISPR/Cas9 en embriones humanos para el estudio del desarrollo embrionario temprano. EMBRYOCRISPR. Instituto de Salud Carlos III (ISCIII). Budget: 155.520,4€. 2022-2025. PI: VEIGA LLUCH, ANA.